Sugi Predict

Sugi Predict / Compounds / SCHEMBL481041

SCHEMBL481041

SCHEMBL481041

O=C(O)c1ccnc(F)c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 2/20 0.55
▸ KDM4E B2RXH2 6/20 0.53
▸ ASPH Q12797 1/20 0.53
▸ KDM8 Q8N371 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ KDM4C Q9H3R0 4/20 0.45
▸ KDM5A P29375 3/20 0.45
▸ TSHR P16473 3/20 0.44
▸ KDM4A O75164 3/20 0.40
▸ KDM5B Q9UGL1 2/20 0.40
▸ KEAP1 Q14145 1/20 0.40
▸ NFE2L2 Q16236 1/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ HIF1AN Q9NWT6 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296598 0.84 NAPRT (0.41) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL27747494 0.82 KDM4E (0.41) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL83616 0.79 SMN1; SMN2 (0.59) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL29486104 0.79 SMN1; SMN2 (0.59) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL30803051 0.79 KDM4E (0.68) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL3579780 0.79 KDM4E (0.68) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL27488847 0.78 SMN1; SMN2 (0.57) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL19857453 0.78 KDM4E (0.60) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL8819772 0.78 NAPRT (0.57) NAPRTKDM4EASPHKDM8SMN1; SMN2
SCHEMBL28361885 0.78 NAPRT (0.57) NAPRTKDM4EASPHKDM8SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116472047-B Arylamine derivative, preparation method and medical application thereof 中国医药研究开发中心有限公司 2025-06-17 — — CN disclosed
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 — — US disclosed
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 — — US disclosed
EP-4448522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-10-23 — — EP disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 — — EP disclosed
CN-118488953-A Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors 豪夫迈·罗氏有限公司 2024-08-13 — — CN disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 — — CN disclosed
CN-116472047-A Arylamine derivative, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-07-21 — — CN disclosed
WO-2023110958-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-22 — — WO disclosed
WO-2023078241-A1 AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2023-05-11 — — WO disclosed
EP-1953165-A1 AZA-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-08-06 — — EP disclosed
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative MSD K.K. (JP) 2008-07-17 — — US disclosed
CN-101056861-A Carbamoyl-substituted spiro derivatives BANYU PHARMA CO LTD (JP) 2007-10-17 — — CN disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 — — US disclosed
EP-1802579-A1 3-ARYLAMINO PYRIDINE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2007-07-04 — — EP disclosed
EP-1795527-A1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-13 — — EP disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 — — EP disclosed
US-20060106046-A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient MSD K.K. (JP) 2006-05-18 — — US disclosed
WO-2006045514-A1 3-ARYLAMINO PYRIDINE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2006-05-04 — — WO disclosed
EP-1595867-A1 MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 NAPRT 2451/4885KDM4E 3978/4885ASPH 3608/4885
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS MGLL, LIPC, PNLIP NAPRT 1383/4885KDM4E 2738/4885ASPH 2586/4885
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 NAPRT 675/4885KDM4E 3605/4885ASPH 658/4885
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative HRH3, HRH4, HRH2 NAPRT 3020/4885KDM4E 607/4885ASPH 881/4885
US-20060106046-A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient MCHR1, MC1R, PRLHR NAPRT 3530/4885KDM4E 2138/4885ASPH 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.